Active pharmaceutical ingredients (APIs) are the biologically active components of medications that produce a therapeutic effect. They are essential to treating various health conditions, from infectious diseases to chronic illnesses and mental health disorders. APIs can be derived from natural sources, such as plants, animals, and minerals, or synthesized chemically in a laboratory. Once identified and characterized, APIs are formulated with inactive ingredients like excipients, binders, and fillers to create medication. The production of APIs is a highly regulated process that involves rigorous testing for safety, efficacy, and purity.

Indonesia’s Capacity to Produce APIs

Indonesia has a growing pharmaceutical industry and the potential to produce APIs locally. However, the proportion of API produced in Indonesia is relatively low compared to countries like India and China, major global producers of APIs.

As of 2021, it is estimated that only 20-30% of the APIs used in Indonesia are produced domestically, with the majority being imported from other countries. To increase local production of APIs, the Indonesian government has implemented policies to encourage local production and attract foreign investment in the sector. While the government’s efforts have led to a recent increase in the domestic production of APIs for certain essential drugs and vaccines, Indonesia is still developing its pharmaceutical industry and increasing its capacity for API production.

Why Drug Prices in Indonesia are Higher than in Other Countries?

Compared to other countries, such as India and China, drug prices in Indonesia can be relatively high. This can be attributed to several factors, including the cost of producing and distributing drugs, taxes, and tariffs, and the lack of price regulation for non-essential medicines.

Due to infrastructure, labor costs, and regulations, the cost of producing and distributing drugs in Indonesia can be higher than in some other countries. The cost of producing APIs, which are mostly imported, can also contribute to higher drug prices.

Taxes and tariffs can add to the cost of drugs, as can markups along the supply chain. Furthermore, the need for price regulation for non-essential drugs in Indonesia can lead to higher prices due to marketing and branding costs. This lack of regulation can also result in a lack of competition, further contributing to higher drug prices.

Reducing Drug Pricing and Increasing API Production in Indonesia

A combination of strategies can be employed to reduce drug pricing and increase API production in Indonesia.

Firstly, the government can encourage investment in the pharmaceutical industry by providing incentives and support to local and foreign investors. Promoting research and development can also help identify new APIs and develop new drug formulations, leading to increased local production and lower drug prices.

Secondly, strengthening regulatory oversight can ensure that API production and drug manufacturing meet international quality standards, improving the safety and effectiveness of drugs and increasing public confidence in locally-produced drugs.

Thirdly, improving access to financing can support the growth of the pharmaceutical industry and enable local producers to invest in new equipment and technology.

Fourthly, encouraging competition among drug manufacturers can help to lower drug prices. This can be achieved through policies that promote market competition and prevent monopolies.

Lastly, implementing drug pricing regulations can ensure that essential drugs are affordable and accessible to the public, reducing the cost of medicines for patients and improving access to healthcare.

To increase API production in Indonesia, the government can provide support and incentives to local producers and attract foreign investment. Promoting research and development can also help to identify new APIs and improve the efficiency of production processes.

Furthermore, strengthening the regulatory framework can ensure that API production meets international quality standards and is safe for medication use. Improving access to financing can support the growth of the pharmaceutical industry and enable local producers to invest in new equipment and technology.

APIs are the foundation of modern medicine and play a crucial role in treating a wide range of health conditions. Indonesia has the potential to produce APIs locally. However, the country is still developing its pharmaceutical industry and increasing its capacity for API production. Using imported APIs in Indonesia can contribute to the cost of pharmaceutical drugs. Still, it is not necessarily the sole or primary reason for high drug prices in the country. Factors such as manufacturing and distribution costs, taxes and tariffs, and the lack of price regulation for non-essential drugs can also contribute to higher drug prices.

To reduce drug pricing and increase API production in Indonesia, a combination of strategies can be employed, including encouraging investment in the pharmaceutical industry, promoting research and development, strengthening regulatory oversight, improving access to financing, encouraging competition among drug manufacturers, and implementing drug pricing regulations for essential drugs.

By implementing these strategies, Indonesia can increase its capacity for API production, reduce the cost of drugs, and improve access to affordable and quality healthcare for its citizens.

This post can also be found in https://www.linkedin.com/pulse/active-pharmaceutical-ingredients-apis-foundation-modern-prabowo